Freenome

Using a routine blood draw for early cancer detection.

Freenome's blood tests look beyond mutations to detect the body's own early-warning signs for cancer, incorporating a multidimensional view of both tumor- and immune-derived signatures that enable the early detection of cancer.

Company Information

Sector
Diagnostics
First Investment
Series B
Year Partnered
2019
Status
Active
Location
San Francisco
CEO
Gabriel Otte